Medical Hyperspectral Imaging Market By Component (Hyperspectral Imaging Systems & Cameras, Accessories, Software & Analytics), By Imaging Mode (Snapshot Hyperspectral Imaging, Push-Broom/Line-Scan Hyperspectral Imaging, Other Scanning Technologies), By Application (Wound Care & Tissue Perfusion Assessment, Surgical Guidance & Intraoperative Imaging, Cancer Detection & Tumor Margin Assessment, Pathology & Histology, Skin & Vascular Diagnostics, Biomedical & Clinical Research), By End User (Hospitals & Clinics, Diagnostic & Specialty Centers, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Medical Hyperspectral Imaging Market: Advancing Real-Time Tissue Oxygenation, Surgical Intelligence, and Spectral Diagnostics Across Wound Care, Oncology, and Precision Surgery

The Global Medical Hyperspectral Imaging Market was valued at USD 0.23 billion in 2025 and is projected to reach USD 0.55 billion by 2032, growing at a CAGR of 13.3% during the forecast period.

 

Medical hyperspectral imaging (HSI) is a non-invasive optical imaging technology that evaluates tissue across numerous narrow wavelength bands rather than relying on conventional red, green, and blue imaging. The resulting spectral information can be processed to characterize physiological and biochemical properties such as tissue oxygenation, oxyhemoglobin and deoxyhemoglobin distribution, perfusion, and tissue composition. Because the technology can generate functional information in real time without ionizing radiation and, in many applications, without injectable contrast agents or direct tissue contact, it is gaining clinical relevance in wound assessment, vascular evaluation, surgery, ophthalmology, and broader tissue characterization.

 

Several medical HSI systems have received FDA 510(k) clearance for specialized clinical applications. HyperMed Imaging's HyperView, cleared in 2016, provides non-invasive assessment of superficial tissue oxygenation and has applications in areas such as localized ischemia and wound evaluation. Optina Diagnostics has advanced hyperspectral retinal imaging through its MHRC-C1 system, cleared in 2020, and the newer Optina-4C platform, cleared in 2025, extending the technology into ophthalmic assessment.

 

In surgical imaging, Hypervision Surgical's HYPERSNAP Surgical System received FDA 510(k) clearance in 2025 for intraoperative hyperspectral visualization. The platform combines spectral imaging with AI- and machine-learning-supported image processing to provide real-time visualization and quantitative tissue oxygenation information during open and minimally invasive general surgical procedures. Such capabilities can help surgeons assess tissue perfusion and viability directly during an operation, creating opportunities for HSI to become part of intraoperative decision-making.

 

Outside the United States, Diaspective Vision's TIVITA platform represents another established medical HSI technology. TIVITA Tissue, TIVITA mini, and related configurations are used internationally for applications such as tissue perfusion assessment, wound evaluation, and surgical flap monitoring and carry CE marking in Europe. These systems demonstrate the broader movement toward bedside and operating-room spectral imaging for objective evaluation of microcirculation and tissue viability.

 

Technology development is increasingly focused on making HSI systems smaller, faster, and easier to integrate into existing surgical workflows. On-chip and snapshot hyperspectral sensors are being developed for endoscopic and laparoscopic applications, allowing spectral information to be collected rapidly without relying on large conventional imaging platforms. Collaborations involving semiconductor and photonics developers such as imec are advancing miniaturized spectral sensors that could support real-time evaluation of tissue perfusion and potentially assist with identification of tumor margins during minimally invasive procedures.

 

Artificial intelligence is also becoming increasingly important in the evolution of medical HSI. Machine-learning algorithms can process large spectral datasets and convert complex wavelength information into clinically interpretable maps or visual overlays. Integration of AI with compact imaging sensors, surgical video platforms, and real-time tissue analysis could expand the clinical utility of hyperspectral imaging across surgery, oncology, ophthalmology, vascular care, and wound management.

 

Overall, medical hyperspectral imaging is progressing from specialized tissue oxygenation and retinal imaging systems toward AI-assisted, real-time surgical and minimally invasive platforms. FDA-cleared technologies such as HyperView, Optina's retinal imaging systems, and HYPERSNAP demonstrate growing regulatory acceptance, while CE-marked TIVITA systems and miniaturized on-chip technologies broaden the international and developmental landscape. Continued advances in sensor miniaturization, AI-based interpretation, real-time perfusion mapping, and endoscopic integration are expected to strengthen the clinical role of hyperspectral imaging across multiple medical specialties.

 

Why Are Chronic Wounds Creating Recurring Demand for Medical HSI?

Chronic wound care represents one of the most commercially relevant applications because tissue condition often needs to be assessed repeatedly over weeks or months. Medicare data show that chronic wounds affect about 10.5 million beneficiaries in the United States and account for an estimated USD 22.5 billion in annual Medicare expenditure. Earlier claims analysis also found a shift in wound expenditure toward physician offices, indicating that wound management extends beyond inpatient hospitals into outpatient and ambulatory settings. Portable HSI systems therefore have an opportunity to compete where clinicians need repeatable information about oxygenation and perfusion without invasive testing. HyperMed's handheld HyperView system is designed around this requirement, providing contact-free measurements of O2 saturation, oxyhemoglobin, and deoxyhemoglobin in superficial tissue.

The UK provides another indication of the recurring workload associated with wound management. An NHS-linked cohort estimated 3.8 million adult patients with wounds in 2017/2018, including approximately 326,000 diabetic foot-ulcer patients, 560,000 patients with venous leg ulcers, and 202,000 with pressure ulcers. Only 49% of chronic wounds healed during the study year, and wound management generated 54.4 million district or community nurse visits and 53.6 million healthcare-assistant visits. The study estimated annual NHS wound-management costs at £8.3 billion. Although these figures are historical and should not be interpreted as current HSI users, they show why objective wound-assessment tools may have value in care pathways involving repeated visits and high staff utilization.

Clinical evidence is progressing but remains an adoption constraint. A 2025 systematic review and meta-analysis evaluating HSI for diabetic foot-ulcer healing included nine publications and 142 participants. The diagnostic meta-analysis reported pooled sensitivity of 0.84 and specificity of 0.79 for predicting ulcer healing. The evidence supports further clinical development, but the limited patient numbers also explain why hospitals and payers may require larger prospective studies before treating HSI as a routine reimbursable wound-management tool.

 

Why Is Intraoperative Imaging Becoming a Major Growth Opportunity?

Surgical HSI is moving closer to routine clinical workflow because newer systems can acquire spectral information fast enough to provide surgeons with real-time or near-real-time information. Rather than introducing an entirely separate diagnostic visit, HSI can potentially be integrated into an existing operation to assess perfusion, superficial tissue oxygenation, bowel viability, graft reperfusion, or other tissue characteristics. Hypervision Surgical's HyperSnap represents this shift from laboratory hyperspectral cameras toward purpose-built surgical systems. Its FDA-cleared platform augments conventional surgical visualization with oxygen-saturation information without requiring an injected fluorescent agent.

The clinical evidence base is also expanding. A 2026 systematic review of intraoperative HSI in abdominal surgery included 13 human studies involving 391 patients across colorectal surgery, mesenteric ischemia, esophageal reconstruction, pancreatic surgery, hepatectomy, and transplantation. The review found that HSI could detect differences between visually selected tissue boundaries and measured perfusion, although evidence remained dominated by relatively small clinical studies and no randomized trials were identified. This creates an attractive but still evidence-dependent market: hospitals can see a possible intraoperative use case, while vendors still need to demonstrate whether the additional imaging information reduces complications or changes surgical decisions consistently.

Hospital procedure volumes provide the commercial setting for this technology. NHS England reported a record 18.4 million elective treatments and operations in 2025, compared with 18.0 million in 2024. England also had 116 elective surgical hubs operating by April 2025. In systems trying to expand theatre capacity and shorten waiting lists, a surgical imaging system is more commercially attractive when it can be integrated with existing visualization equipment without substantially extending operating time.

 

How Could Oncology Increase the Strategic Value of HSI?

Oncology represents a longer-term opportunity because spectral differences between tissue types may help algorithms distinguish tumor from surrounding tissue during surgery. A 2025 systematic review of HSI for tumor-resection guidance included clinical and preclinical research covering 2,163 patients. Tumor delineation was one of the central research applications, supporting continued investment in spectral classification and AI-assisted surgical imaging.

Commercial expectations should nevertheless remain measured. The same review concluded that HSI remains at an early stage of technological maturity for tumor-resection guidance and that stronger clinical evidence is required before widespread adoption. This distinction is important because an FDA-cleared surgical HSI platform should not automatically be described as approved for cancer-margin identification unless that specific indication appears in its authorized labeling. Hypervision can therefore use oncology procedures as an important development pathway while its current commercial proposition remains tied to its cleared surgical visualization and tissue-oxygenation functions.

 

Why Is Reimbursement Still a Major Barrier to Wider Adoption?

U.S. reimbursement remains one of the clearest limitations for wound-focused optical tissue assessment. The AMA's February 2025 CPT Editorial Panel actions approved the deletion of Category III code 0631T, which covered transcutaneous visible-light hyperspectral imaging and was scheduled for Category III sundown. The coding change reduces the visibility of a dedicated hyperspectral wound-imaging pathway and increases the importance of demonstrating enough clinical utility to support future coding and payment strategies.

Adjacent payer policy is similarly restrictive. CMS Local Coverage Determination L39385 considers non-contact near-infrared spectroscopy used for wound and surgical-flap assessment experimental and investigational because the Medicare Administrative Contractor found insufficient evidence of effectiveness. NIRS is not identical to hyperspectral imaging, so the policy should not be described as a national HSI-specific non-coverage determination. It nevertheless demonstrates the evidence hurdle faced by optical technologies seeking routine payment for wound oxygenation assessment.

Capital Blue Cross separately addresses transcutaneous visible-light hyperspectral imaging within its wound and burn management policy. Such policies make clinical outcomes increasingly important to commercial adoption. Vendors may need evidence showing that imaging changes treatment decisions, identifies vascular compromise earlier, improves healing-related outcomes, prevents avoidable procedures, or reduces overall resource use rather than simply demonstrating that spectral measurements can be generated reliably.

 

Which Clinical Settings Are Most Likely to Purchase Medical HSI Systems?

Hospitals and academic medical centers are important early adopters because they combine surgery, wound care, oncology research, ophthalmology, vascular services, and clinical trials within the same organization. The CMS Hospital General Information dataset contains all hospitals registered with Medicare, providing a large institutional customer environment for FDA-cleared imaging technologies. Advanced medical centers are also better positioned to fund new imaging equipment before a mature reimbursement route exists because purchasing decisions can be supported by research budgets, capital-equipment programs, or specialty-department priorities.

Specialist wound centers and outpatient practices could become a separate opportunity if portable HSI demonstrates economic value. HyperMed's HyperView is handheld, battery-operated, contact-free, and specifically designed to display superficial-tissue oxygenation information, making the physical form factor better suited to decentralized use than traditional cart-based spectral equipment. Wider penetration, however, depends heavily on reimbursement and evidence that the information changes wound-management decisions.

Operating rooms represent a different purchasing route. Rather than competing only as standalone diagnostic systems, surgical HSI suppliers can integrate spectral capability with endoscopes, surgical cameras, visualization stacks, and software platforms already purchased by hospitals. This model is visible in KARL STORZ's acquisition of Diaspective Vision's medical spectral-imaging assets and expertise, which can allow HSI functionality to become part of a broader surgical-imaging ecosystem.

 

How Is the Medical Hyperspectral Imaging Market Segmented?

By Component

Hyperspectral Imaging Systems & Cameras accounted for 62.0% of the Medical Hyperspectral Imaging Market in 2025, representing USD 142.6 million, and are projected to grow at a CAGR of 12.8%. Systems and cameras remain the largest component because hospitals, specialty centers, and research institutions require spectral acquisition hardware before software-based tissue analysis can be performed. Demand is supported by the transition from laboratory-grade equipment toward portable, handheld, snapshot, and operating-room-compatible platforms. Companies such as HyperMed Imaging and Hypervision Surgical are developing purpose-built clinical systems that combine spectral capture with tissue oxygenation or intraoperative visualization, while KARL STORZ is integrating spectral capabilities into its broader surgical imaging ecosystem.

Accessories represented 18.0% of the market in 2025, equivalent to USD 41.4 million, and are expected to grow at a CAGR of 11.7%. This segment includes supporting illumination systems, optics, mounts, adapters, calibration components, and other hardware needed to maintain imaging accuracy across different clinical environments. Demand expands with the installed base of HSI cameras because hospitals require application-specific accessories for operating rooms, wound clinics, research laboratories, and endoscopic procedures. Suppliers with modular imaging architectures can capture recurring accessory demand as hospitals adapt the same HSI platform to different procedures and clinical departments.

Software & Analytics held 20.0% of the market in 2025, valued at USD 46.0 million, and are projected to expand at the fastest component CAGR of 15.6%. Growth is being driven by the need to convert complex spectral datasets into clinically interpretable maps and decision-support outputs rather than requiring clinicians to analyze raw wavelength information. Automated spectral reconstruction, tissue classification, oxygenation mapping, visualization, and AI-based analytics increasingly determine the practical value of an HSI platform. For instance, Hypervision Surgical combines hyperspectral acquisition with computational reconstruction and software-generated oxygenation information, while Optina Diagnostics is developing retinal hyperspectral imaging alongside AI-enabled analytical capabilities.

 

By Imaging Mode

Snapshot Hyperspectral Imaging accounted for 47.0% of the market in 2025, representing USD 108.1 million, and is projected to grow at a CAGR of 15.2%. Snapshot imaging leads because it captures spatial and spectral information rapidly without mechanically scanning across the entire field of view, making it particularly suitable for dynamic clinical environments. Its ability to support real-time or near-real-time visualization is increasingly relevant in surgery, where tissue movement and procedure speed limit the practicality of slower scanning approaches. Hypervision Surgical's HyperSnap demonstrates this commercial direction by using snapshot hyperspectral sensing and computational reconstruction to provide intraoperative tissue oxygenation information.

Push-Broom/Line-Scan Hyperspectral Imaging represented 36.0% of the market in 2025, equivalent to USD 82.8 million, and is expected to grow at a CAGR of 11.8%. Line-scan systems remain important in research, pathology, and controlled imaging environments where high spectral resolution can be prioritized over instantaneous image capture. The technology acquires spectral information sequentially across lines of the target, making it suitable for stationary specimens, tissue samples, and laboratory studies. Demand continues through academic research institutes, biomedical laboratories, and pathology-development programs that require detailed spectral datasets for algorithm training and tissue characterization.

Other Scanning Technologies accounted for 17.0% of the market in 2025, valued at USD 39.1 million, and are projected to grow at a CAGR of 12.4%. This category includes alternative spectral acquisition approaches used in specialized clinical and research applications where different combinations of spatial resolution, spectral resolution, imaging speed, and field of view are required. Demand is supported by continuing experimentation with multispectral and hyperspectral architectures across ophthalmology, microscopy, dermatology, pathology, and biomedical research. Technology developers are increasingly selecting imaging modes according to workflow requirements rather than attempting to use one acquisition architecture across every clinical application.

 

By Application

Wound Care & Tissue Perfusion Assessment accounted for 27.0% of the market in 2025, representing USD 62.1 million, and is projected to grow at a CAGR of 14.7%. This is the largest application because chronic wounds require repeated assessment of tissue condition and because oxygenation and perfusion information can complement conventional visual examination. The sizeable Medicare chronic-wound population and the high frequency of wound-related outpatient and community care create a recurring clinical workflow for non-invasive imaging. HyperMed Imaging's HyperView is positioned directly in superficial tissue oxygenation assessment, providing contact-free measurements of oxygen saturation, oxyhemoglobin, and deoxyhemoglobin.

Surgical Guidance & Intraoperative Imaging held 22.0% of the market in 2025, valued at USD 50.6 million, and is expected to grow at a CAGR of 14.2%. Demand is increasing as hyperspectral systems become fast enough to operate within surgical workflows and provide perfusion or oxygenation information without requiring an injected contrast agent. Hospitals are evaluating HSI for colorectal procedures, transplantation, bowel viability assessment, and other surgeries where tissue perfusion can influence operative decisions. Providers such as Hypervision Surgical are advancing real-time HYPERSNAP imaging, while KARL STORZ is expanding spectral imaging capabilities through technologies associated with Diaspective Vision and TIVITA Mini.

Cancer Detection & Tumor Margin Assessment represented 19.0% of the market in 2025, equivalent to USD 43.7 million, and is projected to record the fastest application CAGR of 15.8%. Growth is being driven by research into spectral differences between malignant and surrounding healthy tissues and the potential to provide surgeons with additional information during tumor resection. A 2025 systematic review of tumor-resection guidance included research covering 2,163 patients, showing growing clinical interest while also confirming that stronger validation remains necessary. Early innovation includes AI-assisted spectral classification approaches designed to distinguish tissue types more rapidly during surgery, although commercial claims must remain aligned with the specific regulatory indications of individual devices.

Pathology & Histology accounted for 12.0% of the market in 2025, representing USD 27.6 million, and is projected to grow at a CAGR of 11.6%. Hyperspectral imaging is used in pathology research to obtain richer spectral information from tissue sections than conventional RGB microscopy can provide. This supports development of tissue-classification algorithms, digital pathology research, biomarker identification, and automated image-analysis methods. Demand is concentrated primarily in research institutions, pathology laboratories, and technology-development programs because widespread routine diagnostic use still requires standardized acquisition protocols and validated clinical algorithms.

Skin & Vascular Diagnostics represented 11.0% of the market in 2025, equivalent to USD 25.3 million, and is expected to grow at a CAGR of 12.5%. Growth is supported by the ability of HSI to assess superficial tissue properties without contact or ionizing radiation, making skin and vascular applications technically compatible with spectral imaging. Tissue oxygenation and hemoglobin-related information can be relevant where clinicians evaluate perfusion, vascular compromise, tissue viability, and superficial lesions. Firms such as HyperMed Imaging have developed handheld spectral systems specifically suited to superficial-tissue assessment, supporting the potential use of HSI outside centralized imaging departments.

Biomedical & Clinical Research accounted for 9.0% of the market in 2025, valued at USD 20.7 million, and is projected to grow at a CAGR of 10.8%. Research remains essential to the HSI ecosystem because many emerging applications are still progressing through feasibility studies, algorithm development, clinical validation, and workflow testing. Universities and academic hospitals use HSI to investigate tissue perfusion, oncology, surgery, retinal biomarkers, wound healing, and spectral classification. Research activity also creates datasets that commercial developers can use to improve image reconstruction and AI-assisted interpretation before expanding into regulated clinical applications.

 

By End User

Hospitals & Clinics accounted for 43.0% of the market in 2025, representing USD 98.9 million, and are projected to grow at a CAGR of 14.1%. Hospitals lead because they concentrate the procedures and specialties most relevant to medical HSI, including surgery, wound management, vascular care, ophthalmology, oncology, and advanced diagnostic imaging. They also have greater capacity to purchase capital imaging equipment and participate in clinical validation programs. Key players such as Hypervision Surgical and KARL STORZ are increasingly designing spectral systems around operating-room integration, while HyperMed's portable platform expands the opportunity into wound and vascular clinics.

Diagnostic & Specialty Centers represented 24.0% of the market in 2025, equivalent to USD 55.2 million, and are expected to grow at a CAGR of 13.6%. These facilities are becoming important users as portable and specialty-focused HSI devices reduce dependence on large hospital imaging departments. Wound centers, ophthalmology clinics, vascular practices, dermatology facilities, and other specialty providers can use targeted spectral systems where repeated imaging is part of ongoing patient assessment. Optina Diagnostics' retinal hyperspectral portfolio demonstrates how HSI can be developed around a specific specialty workflow rather than sold only as a general-purpose hospital imaging platform.

Academic & Research Institutes held 20.0% of the market in 2025, valued at USD 46.0 million, and are projected to grow at a CAGR of 11.3%. Universities and research hospitals remain major purchasers because many medical HSI applications are still undergoing clinical validation and algorithm development. These institutions investigate new spectral biomarkers, tumor classification, perfusion assessment, surgical guidance, pathology, and image-processing techniques while also providing early clinical environments for emerging companies. King's College London's relationship with Hypervision Surgical illustrates how academic research can support technology development that later progresses toward regulatory clearance and commercialization.

Pharmaceutical & Biotechnology Companies accounted for 13.0% of the market in 2025, representing USD 29.9 million, and are projected to grow at a CAGR of 14.8%. Demand is increasing as life-science companies use advanced optical imaging for preclinical research, tissue analysis, treatment-response studies, biomarker exploration, and drug-development workflows. HSI can provide spatial and biochemical information without destroying tissue samples, supporting repeated analysis and detailed characterization in selected research programs. Pharmaceutical and biotechnology demand also benefits suppliers of research-grade cameras, analytical software, and customized spectral platforms that can be integrated into laboratory workflows.

 

Why Is North America an Important Medical HSI Market?

North America has the clearest regulatory commercialization pathway because multiple HSI products have already received FDA clearance. HyperMed's HyperView established a tissue-oxygenation pathway, Optina Diagnostics established an ophthalmic hyperspectral-camera pathway, and Hypervision Surgical added an intraoperative surgical application in 2025. These clearances give U.S. hospitals clinically regulated products rather than research-only spectral cameras. North America accounted for a 42.0% market share in 2025, reaching USD 96.6 million, and is projected to grow at a CAGR of 11.9% during the forecast period.

Demand is also supported by a significant chronic-disease burden. IDF estimates that 56 million adults in North America and the Caribbean were living with diabetes in 2024, while U.S. Medicare data indicate approximately 10.5 million beneficiaries are affected by chronic wounds. However, reimbursement remains a counterweight to adoption, particularly in wound imaging, where optical tissue-assessment policies remain restrictive.

 

Why Is Europe Emerging as a Center for Surgical HSI Development?

Europe combines high surgical activity with several important HSI technology developers and accounted for 28.0% of the market in 2025, representing USD 64.4 million, and is projected to grow at a CAGR of 12.6%.

The commercial ecosystem is also strengthening. In April 2025, Germany-based KARL STORZ acquired intellectual property, assets, and personnel from Diaspective Vision, which had developed hyperspectral and multispectral cameras for medical applications. KARL STORZ identified the TIVITA Mini endoscopic system as a particular focus; the device is CE-certified under the extended Medical Device Directive timeline as a Class IIa system for contact-free and dye-free assessment of tissue perfusion and oxygenation.

The UK is another important development center. King's College London reported in April 2026 that spinout Hypervision Surgical raised £17 million in Series A financing to advance deployment of its UK-certified and FDA-cleared HYPERSNAP system. Together with NHS clinical development and England's record elective activity, this gives Europe a combination of academic research, clinical validation, surgical volume, venture funding, and established endoscopy companies.

 

Why Could Asia-Pacific Become a Major Long-Term Demand Region?

Asia-Pacific accounted for a 22.0% market share in 2025, valued at USD 50.6 million, and is projected to grow at a CAGR of 15.9%, supported by a large diabetes burden—particularly 107 million adults in South-East Asia alone—which is expected to drive long-term demand for wound, retinal, vascular, and surgical imaging applications.

Adoption is likely to be concentrated initially in tertiary hospitals, university medical centers, advanced surgical institutions, and research programs because HSI remains a specialized capital technology. Global surgical-imaging companies such as KARL STORZ already operate across the region, which could make integration into established endoscopy platforms a more practical route to adoption than building a new standalone HSI purchasing category.

 

What Could Drive Medical HSI Adoption in Latin America?

Latin America accounted for a 5.0% market share in 2025, with a market size of USD 11.5 million, and is projected to grow at a CAGR of 13.4%, driven by the rising chronic disease burden and gradual expansion of advanced hospital imaging, particularly as 35 million adults in South and Central America were living with diabetes in 2024, increasing demand for diabetic vascular, retinal, and wound-related care.

Near-term adoption is likely to remain concentrated in major urban hospitals and private or academic medical centers because reimbursement, capital budgets, and specialist availability vary substantially across countries. International suppliers with established surgical or imaging distribution networks may therefore be better positioned than companies depending on direct sales of standalone hyperspectral equipment.

 

How Could the Middle East and Africa Develop as Future HSI Markets?

The Middle East & Africa region accounted for a 3.0% market share in 2025, with a market size of USD 6.9 million, and is projected to grow at a CAGR of 12.8% during the forecast period.

Africa presents a different adoption environment. IDF reports particularly high levels of undiagnosed diabetes in the region, which indicates substantial unmet diagnostic and chronic-care need but also reflects limitations in healthcare access. Medical HSI commercialization is therefore more likely to begin in tertiary hospitals and specialist centers rather than broad community deployment. Portable systems could eventually improve accessibility, but cost, clinician training, service infrastructure, and reimbursement remain important barriers.

 

Which Companies Are Shaping Competition in Medical Hyperspectral Imaging?

How Hypervision Surgical Is Building Its HYPERSNAP Portfolio?

Hypervision Surgical is focused on real-time hyperspectral imaging for surgery. Its principal commercial platform is HYPERSNAP, which combines a snapshot spectral camera, conventional RGB visualization, computational reconstruction, and software-generated tissue oxygenation information for intraoperative use. The HyperSnap Surgical System received FDA 510(k) clearance in June 2025, strengthening the company's ability to move from development programs into U.S. commercial deployment.

The company's portfolio strategy is increasingly centered on integration with surgical workflow rather than standalone spectral-image acquisition. King's College London reported that Hypervision raised £17 million in Series A funding in April 2026 to advance its HYPERSNAP platform. The financing gives the company additional resources for commercialization, clinical evidence generation, and expansion of surgical-intelligence applications.

 

How KARL STORZ Is Expanding Its Spectral Surgical-Imaging Portfolio?

KARL STORZ has a broad surgical visualization, endoscopy, operating-room integration, camera, and digital-surgery portfolio. In the HSI field, its strategic position strengthened through the April 2025 acquisition of Diaspective Vision's relevant intellectual property, assets, and personnel. Diaspective had developed hyperspectral and multispectral systems for clinical and preclinical applications.

A key product associated with this technology is TIVITA Mini, an endoscopic spectral-imaging system designed for contact-free and dye-free assessment of tissue perfusion and oxygenation. Incorporating spectral technology into KARL STORZ's established endoscopy and OR ecosystem could lower procurement barriers because hospitals may be able to adopt HSI as an extension of existing visualization infrastructure rather than as an isolated imaging category.

 

HyperMed Imaging Positioned in Tissue Oxygenation

HyperMed Imaging is primarily positioned around superficial-tissue oxygenation. Its HyperView platform is an FDA-cleared handheld and battery-operated hyperspectral imaging device that reports approximate oxygen saturation, oxyhemoglobin, and deoxyhemoglobin levels and presents the information through two-dimensional color-coded maps.

The portfolio is particularly relevant to vascular compromise and wound-related assessment because HyperView does not require contact with the patient or injectable contrast. HyperMed's earlier OxyVu-1 platform was also FDA cleared, but the company states that it is no longer manufactured or sold. HyperView therefore represents the company's current commercial hyperspectral tissue-oximetry offering.

 

Optina Diagnostics Developing Retinal HSI

Optina Diagnostics provides a different competitive approach by concentrating on retinal hyperspectral imaging rather than wound or surgical perfusion. Its Mydriatic Hyperspectral Retinal Camera MHRC-C1 received FDA clearance in April 2020 and was designed to capture multiple monochromatic retinal images across different wavelengths.

The newer Optina-4C, cleared in September 2025, captures a series of 92 high-resolution retinal images at precise wavelength intervals. Optina's broader strategy combines retinal spectral imaging with AI-enabled clinical decision analytics, giving the company a differentiated position in ophthalmic imaging and potential retinal biomarker development rather than direct competition with surgical HSI platforms.

 

Analyst Perspective: What Will Determine the Next Phase of the Medical HSI Market?

The next stage of competition will depend less on whether hyperspectral cameras can detect spectral differences and more on whether those signals can be turned into fast, clinically useful information. Early studies in wound care and surgery suggest HSI may help assess oxygenation, perfusion, bowel viability, and tumor margins, but most evidence is still based on small studies with limited large-scale clinical validation.

Real-time imaging is improving usability. Systems like Hypervision Surgical’s HYPERSNAP enable video-rate surgical visualization, while KARL STORZ is integrating spectral imaging into endoscopic platforms through technologies such as TIVITA. As a result, competition is shifting toward workflow integration, speed, automation, and compatibility with existing surgical systems rather than spectral resolution alone.

Reimbursement remains a key barrier, especially in wound care. The removal of CPT Category III code 0631T and limited coverage for similar optical technologies highlight the challenge of securing consistent payment. Future adoption will depend on proving that HSI improves outcomes, reduces complications, or lowers overall care costs.

Near-term momentum is strongest in surgical imaging, tissue oxygenation, and ophthalmology, supported by FDA-cleared products and recent investments such as Hypervision’s £17 million funding round and KARL STORZ’s acquisition of Diaspective Vision assets. Wider adoption will depend on stronger clinical evidence and easier integration into everyday clinical workflows.

 

Medical Hyperspectral Imaging Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.23 Billion
Revenue Forecast in 2032	USD 0.55 Billion
Overall Growth Rate	CAGR of 13.3% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Component, By Imaging Mode, By Application, By End User, By Geography
By Component	Hyperspectral Imaging Systems & Cameras, Accessories, Software & Analytics
By Imaging Mode	Snapshot Hyperspectral Imaging, Push-Broom/Line-Scan Hyperspectral Imaging, Other Scanning Technologies
By Application	Wound Care & Tissue Perfusion Assessment, Surgical Guidance & Intraoperative Imaging, Cancer Detection & Tumor Margin Assessment, Pathology & Histology, Skin & Vascular Diagnostics, Biomedical & Clinical Research
By End User	Hospitals & Clinics, Diagnostic & Specialty Centers, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising adoption of real-time tissue oxygenation assessment, increasing demand for non-invasive wound monitoring, growing use of intraoperative imaging technologies, AI integration in spectral diagnostics, expansion of precision surgery and advanced optical imaging applications
Customization Option	Available upon request